中村 善雄 (ナカムラ ヨシオ)

Nakamura, Yoshio

写真a

所属(所属キャンパス)

医学部 皮膚科学教室 (信濃町)

職名

助教(有期)

特記事項

Nakamura

経歴 【 表示 / 非表示

  • 2006年04月
    -
    2008年03月

    東京厚生年金病院

  • 2008年04月
    -
    2009年06月

    慶応義塾大学医学部皮膚科

  • 2009年07月
    -
    2011年10月

    荻窪病院皮膚科

  • 2011年10月
    -
    2014年06月

    慶応義塾大学医学部皮膚科

  • 2014年07月
    -
    継続中

    国立がん研究センター中央病院

全件表示 >>

学歴 【 表示 / 非表示

  • 2000年04月
    -
    2006年03月

    金沢大学, 医学部, 医学科

    大学, 卒業

  • 2014年04月
    -
    2018年03月

    慶應義塾, 医学研究科, 医療科学系

    大学院, 単位取得退学

免許・資格 【 表示 / 非表示

  • 医師免許, 2006年04月

  • 日本皮膚科学会認定皮膚科専門医, 2011年10月

  • 日本がん治療認定医機構認定がん治療認定医, 2014年04月

  • 日本皮膚科学会認定皮膚悪性腫瘍指導専門医, 2017年04月

 

研究分野 【 表示 / 非表示

  • 皮膚科学

研究キーワード 【 表示 / 非表示

  • 皮膚がん

  • 腫瘍外科

 

論文 【 表示 / 非表示

  • Serum cytokeratin 19 fragment 21-1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary Paget disease

    Nakamura Y., Tanese K., Hirai I., Amagai M., Kawakami Y., Funakoshi T.

    British Journal of Dermatology (British Journal of Dermatology)  181 ( 3 ) 535 - 543 2019年09月

    ISSN  00070963

     概要を見る

    © 2019 British Association of Dermatologists Background: Extramammary Paget disease (EMPD) is a rare intraepithelial adenocarcinoma affecting the genitals and axillary regions. As metastasis of these tumours is itself rare, solid disease management strategies have not been established. Serum carcinoembryonic antigen (CEA) and cytokeratin 19 fragment 21-1 (CYFRA 21-1) levels have been identified as candidate biomarkers for tumour progression in EMPD. Objectives: To determine the accuracy of and the correlation between these markers in patients with EMPD. Methods: Serum CEA and CYFRA 21-1 levels were examined in 30 patients with EMPD treated at Keio University Hospital, and compared against clinical information. Both assays were performed at the time of diagnosis, during the postoperative observation period, and following systemic treatment in those with confirmed metastasis. Serum levels were then correlated with tumour progression status and treatment responses. Results: Normal levels for both assays were observed in all 11 patients with primary localized disease (100%). In patients with metastatic disease the CEA positivity rate was 79% (15 of 19 patients), with a rate of 63% (12 of 19 patients) for CYFRA 21-1. Changes in CEA and CYFRA 21-1 levels were statistically independent; however, using a combined view, elevated levels of either marker improved the positivity rate to 95% (18 of 19 patients). Use of both markers also correlated well with treatment responses. Conclusions: The combination of CEA and CYFRA 21-1 is useful for predicting metastasis and treatment response in patients with EMPD, especially in those who only have elevation of a single marker. What's already known about this topic?. Serum levels of carcinoembryonic antigen (CEA) and cytokine 19 fragment 21-1 (CYFRA 21-1) have been shown to be elevated in patients with extramammary Paget disease (EMPD). Elevation of serum CEA levels is associated with tumour progression of EMPD. A single small study reported that serum CYFRA 21-1 levels are elevated in patients with EMPD with lymph node metastasis. What does this study add?. Serum CEA and CYFRA 21-1 were present in 79% and 63% of 19 cases of metastatic EMPD, respectively. Elevations of CEA and CYFRA 21-1 were statistically independent. CEA and CYFRA 21-1 combination assays were positive in 95% of cases of metastatic EMPD. What is the translational message?. Combination assays with CEA and CYFRA 21-1 are useful for monitoring treatment response in patients with metastatic EMPD, particularly in those with elevation of either marker.

  • Combination Cisplatin-Epirubicin-Paclitaxel Therapy for Metastatic Extramammary Paget's Disease

    Hirai I., Tanese K., Nakamura Y., Ishii M., Kawakami Y., Funakoshi T.

    Oncologist (Oncologist)  24 ( 6 ) e394 - e396 2019年06月

    ISSN  10837159

     概要を見る

    © AlphaMed Press 2019 Extramammary Paget's disease (EMPD) is a rare cutaneous adenocarcinoma that clinicopathologically resembles breast cancer. The prognosis of metastatic EMPD is poor. Although several chemotherapies have been tried, the effects are temporary; better drugs and combinations are required. In the present study, we retrospectively analyze the efficacy and safety of combination of cisplatin, epirubicin, and paclitaxel in five metastatic EMPD cases. The efficacy was better than that for previously reported regimens: 80% partial responses, including two patients who were refractory to taxane- and/or platinum-based regimens. In terms of safety, four patients who were able to continue treatment exhibited acceptable tolerability. This is the first regimen to combine taxane and anthracycline. When treating breast cancer, anthracycline is regarded as the key cytotoxic agent, and anthracycline in combination with taxane constitutes a key chemotherapeutic regimen. Given our results, we speculate both drugs are critical chemotherapeutic agents for the treatment of metastatic EMPD.

  • Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab

    Muto Y., Kitano S., Tsutsumida A., Namikawa K., Takahashi A., Nakamura Y., Yamanaka T., Yamamoto N., Yamazaki N.

    Journal of Dermatology (Journal of Dermatology)  46 ( 6 ) 498 - 506 2019年06月

    ISSN  03852407

     概要を見る

    © 2019 Japanese Dermatological Association Melanoma is one of the most serious form of skin cancer. Nowadays, ipilimumab is used for advanced melanoma refractory to first-line anti-programmed death 1 (PD-1) antibodies. Thirty patients (male : female ratio, 18:12; median age, 60.5 years) sequentially treated with ipilimumab after anti-PD-1 antibody (nivolumab or pembrolizumab), while 58 (male : female ratio, 27:31; median age, 66.5 years) with anti-PD-1 antibody only. The kind of therapy and schedules were as follows: nivolumab, 2 mg/kg at 3-week intervals or at 3 mg/kg every 2 week; pembrolizumab, 2 mg/kg every 3 weeks; ipilimumab, 3 mg/kg at 3-week intervals for four doses. The sequential therapy was selected for the patients with disease progression and/or recovered from severe (immune-related [ir]) adverse events (AE) after PD-1 blockade monotherapy. We evaluated multiple parameters and analyzed their relevance to overall survival (OS). The best objective response rate was 6.7% in sequential ipilimumab treatment. Median OS was 163 days (range, 16–489). Baseline absolute lymphocyte count (ALC) and performance status (PS) before sequential ipilimumab were associated with OS in univariate analyses. Baseline PS and irAE within 6 weeks after ipilimumab administration showed significant differences on multivariate analysis. Prior to first-line PD-1 blockade, these parameters were not associated with OS. The other factors (i.e. age, sex, number of doses, absolute neutrophil counts, neutrophil : lymphocyte ratio, lactate dehydrogenase and C-reactive protein) were not associated with OS. [Correction added on 17 April 2019, after first online publication: ‘not related to OS' has been amended to ‘not associated with OS’.] Ipilimumab as sequential therapy did not appear to improve OS and was associated with more severe irAE than PD-1 blockade monotherapy. We need to carefully consider treating patients with poor PS and low ALC.

  • Updates on the systemic treatment of advanced non-melanoma skin cancer

    Tanese K., Nakamura Y., Hirai I., Funakoshi T.

    Frontiers in Medicine (Frontiers in Medicine)  6 2019年

     概要を見る

    © 2019 Tanese, Nakamura, Hirai and Funakoshi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Non-melanoma skin cancers (NMSCs), which represent a diverse group of cutaneous malignancies, are the most common forms of human neoplasia. The incidence of these diseases is increasing due to a number of factors, including that of increasing human lifespans. The majority of NMSCs are basal cell carcinomas (BCC) and cutaneous squamous cell carcinomas (cSCC), with the remainder being various rare skin cancers, including extramammary Paget's disease (EMPD), Merkel cell carcinoma (MCC), and several skin adnexal carcinomas. Of these, MCC usually shows aggressive behavior with a high mortality rate. On the other hand, BCC, cSCC, EMPD, and skin adnexal tumors usually show an indolent clinical course and metastasize only rarely. Nevertheless, the metastatic forms of these tumors commonly lead to poor patient outcome. A definitive management strategy for the treatment of advanced NMSC has not been established, mainly due to their rarity and lack of reliable information based on well-controlled randomized trials. Chemotherapeutic regimens for treatment of these diseases have been mainly based on the observations of isolated, small case series or clinical trials with a limited numbers of patients. However, accumulating evidence regarding their pathobiological backgrounds as well as recent advances in molecular biotechnology have facilitated the development of novel drugs for treatment of these diseases. Over the past decade, the U.S. Food and Drug Administration has approved several molecular targeting therapies, including Hedgehog inhibitors for BCC, monoclonal antibodies targeting anti-programmed death ligand-1 and anti- programmed cell death 1 (PD-1) for MCC, and anti-PD-1 for cSCC. Here, we review their clinical utility and discuss updated systemic treatment strategies for advanced NMSC.

  • 皮膚上皮系悪性腫瘍に対するカルボプラチン・エピルビシン併用療法:6例の後ろ向き研究

    中村 善雄

    J Dermatol 45 ( 7 ) 874 - 875 2018年07月

全件表示 >>

KOARA(リポジトリ)収録論文等 【 表示 / 非表示

総説・解説等 【 表示 / 非表示

研究発表 【 表示 / 非表示

  • Analysis Of The Appropriate Margin Of Pigmented Bcc: A Single Institute Retrospective Study In Japan

    中村 善雄

    World congress on cancers of the skin (Sydney) , 2018年08月

  • Retrospective Study Of Chemotherapy Using Carboplatin And Epirubicin For Advanced Epithelial Malignancy Of The Skin. World congress on cancers of the skin

    中村 善雄

    World congress on cancers of the skin (Sydney) , 2018年08月

  • Pretreatment prognostic factors and early markers for outcome in advanced melanoma treated with nivolumab

    中村 善雄

    ESMO 2016 congress (Copenhagen) , 2016年10月, ESMO

  • Outcomes of local treatment for malignant melanoma brain metastases: a single institution retrospective study

    中村 善雄

    European Cancer Congress (Vienna) , 2015年09月